Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty - PubMed (original) (raw)

Clinical Trial

Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty

K Watanabe et al. Am Heart J. 1996 Jul.

Abstract

This protocol was performed to elucidate the preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty (PTCA). A total of 118 patients with 134 vessels undergoing successful PTCA was randomly and prospectively assigned to the probucol group (group P) or the control group (group C). The subjects consisted of 91 men and 27 women, with a mean age of 63.4 +/- 2.3 years. Sixty-six vessels of 59 patients in group P and 68 vessels of 59 patients in group C were evaluated by coronary angiography at 3 months after PTCA. Probucol (0.5 mg/day) was administered between >7 days before PTCA and 3 months after PTCA. The serum total cholesterol (TC) level and the formula low-density lipoprotein cholesterol (formula LDL-C) in group P decreased from 203.8 +/- 43.1 to 169.6 +/- 39.4 mg/dl and from 131.4 +/- 0.7 to 108.7 +/- 2.5 mg/dl, whereas in group C, the levels decreased only from 202.3 +/- 32.1 to 194.2 +/- 29.8 mg/dl and from 129.2 +/- 38.1 to 124.3 +/- 31.7 mg/dl, respectively. The restenosis rate was significantly lower in group P (19.7%; 13 of 66 vessels) than in group C (39.7%; 27 of 68 vessels; p < 0.05). In group P, the probucol blood concentration was significantly higher in the subjects without restenosis (31 +/- 9 microg/ml) than in those with restenosis (18 +/- 8 microg/ml; p < 0.01), but the serum TC and formula LDL-C levels were not significantly different between these two groups. In summary, long-term administration of probucol significantly reduces the incidence of restenosis after PTCA. it was suggested that the mechanism of this preventive effect was not reducing the serum TC or formula LDL-C levels, but rather an inhibitory action on smooth muscle cell proliferation.

PubMed Disclaimer

Similar articles

• Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
  Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamaguchi H. Yokoi H, et al. J Am Coll Cardiol. 1997 Oct;30(4):855-62. doi: 10.1016/s0735-1097(97)00270-2. J Am Coll Cardiol. 1997. PMID: 9316509 Clinical Trial.
• Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]).
  Daida H, Kuwabara Y, Yokoi H, Nishikawa H, Takatsu F, Nakata Y, Kutsumi Y, Oshima S, Nishiyama S, Ishiwata S, Kato K, Nishimura S, Miyauchi K, Kanoh T, Yamaguchi H. Daida H, et al. Am J Cardiol. 2000 Sep 1;86(5):550-2, A9. doi: 10.1016/s0002-9149(00)01013-4. Am J Cardiol. 2000. PMID: 11009277 Clinical Trial.
• Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty.
  Lee YJ, Daida H, Yokoi H, Miyano H, Takaya J, Sakurai H, Mokuno H, Yamaguchi H. Lee YJ, et al. Jpn Heart J. 1996 May;37(3):327-32. doi: 10.1536/ihj.37.327. Jpn Heart J. 1996. PMID: 8774625 Clinical Trial.
• [Anti-atherogenic drugs].
  Kanaki T, Saito Y. Kanaki T, et al. Nihon Rinsho. 1998 Oct;56(10):2635-9. Nihon Rinsho. 1998. PMID: 9796331 Review. Japanese.
• Ischemia: reperfusion injury and restenosis after coronary angioplasty.
  Park JW, Braun P, Mertens S, Heinrich KW. Park JW, et al. Ann N Y Acad Sci. 1992 Sep 30;669:215-36. doi: 10.1111/j.1749-6632.1992.tb17102.x. Ann N Y Acad Sci. 1992. PMID: 1444028 Review.

Cited by

• Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis.
  Liu J, Li M, Lu H, Qiao W, Xi D, Luo T, Xiong H, Guo Z. Liu J, et al. PLoS One. 2015 Apr 21;10(4):e0124021. doi: 10.1371/journal.pone.0124021. eCollection 2015. PLoS One. 2015. PMID: 25898372 Free PMC article. Review.
• A bumpy and winding but right path to domestic drug-eluting coronary stents.
  Cho JY, Ahn Y, Jeong MH. Cho JY, et al. Korean Circ J. 2013 Oct;43(10):645-54. doi: 10.4070/kcj.2013.43.10.645. Korean Circ J. 2013. PMID: 24255648 Free PMC article. Review.
• Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
  Serebruany V, Malinin A, Qiu FH, Xu XC, Kunsch C, Scott R; ALPS Study Group. Serebruany V, et al. J Thromb Thrombolysis. 2009 May;27(4):438-46. doi: 10.1007/s11239-008-0233-y. Epub 2008 Jun 3. J Thromb Thrombolysis. 2009. PMID: 18521540 Clinical Trial.
• Antioxidants: the good, the bad and the ugly.
  Tardif JC. Tardif JC. Can J Cardiol. 2006 Feb;22 Suppl B(Suppl B):61B-65B. doi: 10.1016/s0828-282x(06)70988-6. Can J Cardiol. 2006. PMID: 16498514 Free PMC article. Review.
• Antioxidants and atherosclerosis: emerging drug therapies.
  Tardif JC. Tardif JC. Curr Atheroscler Rep. 2005 Feb;7(1):71-7. doi: 10.1007/s11883-005-0078-1. Curr Atheroscler Rep. 2005. PMID: 15683606 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations